

Resource Summary Report

Generated by [dkNET](#) on Sep 5, 2026

BJAB

RRID:CVCL_5711

Type: Cell Line

Proper Citation

RRID:CVCL_5711

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_5711

Proper Citation: RRID:CVCL_5711

Description: Cell line BJAB is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Burkitt lymphoma

Defining Citation: [PMID:62724](#), [PMID:171663](#), [PMID:175026](#), [PMID:179629](#), [PMID:1915267](#), [PMID:3495441](#), [PMID:3518877](#), [PMID:4369887](#), [PMID:6231253](#), [PMID:6245632](#), [PMID:6286763](#), [PMID:6600440](#), [PMID:7316467](#), [PMID:8344493](#), [PMID:8515068](#), [PMID:8558920](#), [PMID:10739008](#), [PMID:11226526](#), [PMID:20054396](#), [PMID:23257783](#), [PMID:23292937](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:26589293](#), [PMID:26787899](#), [PMID:29416618](#), [PMID:29666304](#), [PMID:30165192](#), [PMID:31160637](#)

Comments: Virology: EBV-negative. Even so that the original tumor tissue was infected with the B95-8 strain of EBV., Population: African; Kenyan., Part of: LL-100 blood cancer cell line panel.

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: BJAB

Synonyms: BJAb, BJA-B, BJAB-1, BJA-B1, BJA-B-1

Cross References: BTO:BTO_0001931, EFO:EFO_0002815, AddexBio:C0003016/4884, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-7721, ArrayExpress:E-MTAB-7722, BioGRID_ORCS_Cell_line:741, BioSample:SAMN03470800, cancercellines:CVCL_5711, CGH-DB:9192-4, ChEMBL-Cells:ChEMBL3308492, ChEMBL-Targets:ChEMBL613536,

CLS:302006, Cosmic:998715, Cosmic:1019312, Cosmic:1037700, Cosmic:1086323, Cosmic:1127265, Cosmic:1517659, Cosmic:1588562, Cosmic:1945179, DSMZ:ACC-757, DSMZCellDive:ACC-757, EGA:EGAS00001000610, GEO:GSM33155, GEO:GSM710427, GEO:GSM710443, GEO:GSM1059805, GEO:GSM3150240, IARC_TP53:699, Lonza:107, PharmacDB:BJAB_102_2019, PRIDE:PXD012087, Progenetix:CVCL_5711, PubChem_Cell_line:CVCL_5711, TOKU-E:3575, Wikidata:Q50348210

ID: CVCL_5711

Record Creation Time: 20220427T215404+0000

Record Last Update: 20260904T021648+0000

Ratings and Alerts

No rating or validation information has been found for BJAB.

No alerts have been found for BJAB.

Data and Source Information

Source: [CelloSaurus](#)

Usage and Citation Metrics

We found 412 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Enssle JC, et al. (2026) Pathogenesis of diffuse large B cell lymphoma proteogenotypes. Cancer cell, 44(7), 1437.

Probst P, et al. (2025) Broadening the Therapeutic Window of ADCs Using Site-Specific Bioconjugation Showcased by an MMAE-Containing Peptide Linker in a CD79b-Targeting ADC. Molecular cancer therapeutics, 24(6), 803.

Farkas T, et al. (2025) B cell lines fail to support efficient rhesus enteric calicivirus and human norovirus replication. Journal of virology, 99(5), e0014325.

Sahasrabuddhe AA, et al. (2025) The FBXO45-GEF-H1 Axis Controls Germinal Center Formation and B-cell Lymphomagenesis. Cancer discovery, 15(4), 838.

Manara P, et al. (2025) Blocking NRF2 Translation by Inhibition of Cap-Dependent Initiation Sensitizes Lymphoma Cells to Ferroptosis and CAR T-cell Immunotherapy. Cancer research.

Choi J, et al. (2024) Molecular targets of glucocorticoids that elucidate their therapeutic efficacy in aggressive lymphomas. Cancer cell, 42(5), 833.

Scuoppo C, et al. (2024) Repurposing NAMPT Inhibitors for Germinal Center B Cell-Like Diffuse Large B-Cell Lymphoma. *Blood cancer discovery*, 5(6), 417.

Dere RC, et al. (2023) Integrated summary of immunogenicity of polatuzumab vedotin in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma. *Frontiers in immunology*, 14, 1119510.

Partridge W, et al. (2023) Correlations between preclinical BJAB assay ranking of antisense drugs and clinical trial adverse events. *Clinical and translational science*, 16(4), 575.

Fricke T, et al. (2023) Comparison of a Genotype 1 and a Genotype 2 Macaque Foamy Virus env Gene Indicates Distinct Infectivity and Cell-Cell Fusion but Similar Tropism and Restriction of Cell Entry by Interferon-Induced Transmembrane Proteins. *Viruses*, 15(2).

Chen J, et al. (2023) Oncolytic strategy using new bifunctional HDACs/BRD4 inhibitors against virus-associated lymphomas. *PLoS pathogens*, 19(1), e1011089.

Page A, et al. (2023) Engineering B cells with customized therapeutic responses using a synthetic circuit. *Molecular therapy. Nucleic acids*, 33, 1.

Ho JWY, et al. (2023) Comprehensive Profiling of EBV Gene Expression and Promoter Methylation Reveals Latency II Viral Infection and Sporadic Abortive Lytic Activation in Peripheral T-Cell Lymphomas. *Viruses*, 15(2).

Kotzur R, et al. (2023) Eradication of CD48-positive tumors by selectively enhanced YTS cells harnessing the lncRNA NeST. *iScience*, 26(8), 107284.

Wilke NL, et al. (2023) Ruthenium Complex HB324 Induces Apoptosis via Mitochondrial Pathway with an Upregulation of Harakiri and Overcomes Cisplatin Resistance in Neuroblastoma Cells In Vitro. *International journal of molecular sciences*, 24(2).

Li X, et al. (2023) Suppression of KSHV lytic replication and primary effusion lymphoma by selective RNF5 inhibition. *PLoS pathogens*, 19(1), e1011103.

Capolla S, et al. (2023) Targeted chitosan nanobubbles as a strategy to down-regulate microRNA-17 into B-cell lymphoma models. *Frontiers in immunology*, 14, 1200310.

Portelinha A, et al. (2023) Synthetic lethality of drug-induced polyploidy and BCL-2 inhibition in lymphoma. *Nature communications*, 14(1), 1522.

Li S, et al. (2023) Epstein-Barr Virus Synergizes with BRD7 to Conquer c-Myc-Mediated Viral Latency Maintenance via Chromatin Remodeling. *Microbiology spectrum*, 11(2), e0123722.

Grover S, et al. (2023) Characterization of HPV subtypes in invasive cervical cancer in Botswana patients using a pan-pathogen microarray technology. *Tumour virus research*, 15, 200262.